Company news
Recce Pharmaceuticals Ltd. news in 2023
Recce Pharmaceuticals Ltd.'s news releases, calls and decks from 2023, newest first.
Murdoch Children's R327 Efficacy UTI in-vivo
December 27, 2023
RCE Awarded Further $11.17m Advanced Overseas Finding
December 15, 2023
RCE Awarded $43.7m AusIndustry Advanced Overseas Finding
December 14, 2023
Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo
December 13, 2023
Canadian Patent Granted for RECCE Anti-Infectives
November 22, 2023
Subjects Dosed Over 15 mins in UTI/Urosepsis Clinical Trial
November 6, 2023
Committee Approves Fast 15-Min Infusion in Ph I/II Urosepsis
October 23, 2023
Completes Cohort Dosing UTI/Urosepsis Rapid Infusion Trial
September 22, 2023
Placement and Entitlement Offer
September 11, 2023
Opening R&D Address at World AMR Congress
September 7, 2023
RECCE Trademark Registered - Vietnam
September 6, 2023
Additional Positive Patient Cases - Special Access Scheme
August 31, 2023
Appendix 4E and Unaudited Preliminary Report
August 31, 2023
Next Dose Cleared in Rapid Infusion Phase I/II UTI Trial
August 28, 2023
Patients Dosed in R327 Diabetic Foot Infection Trial
August 22, 2023
Phase I/II Burn Wound Infection Trial Stage 1 Complete
August 21, 2023
Positive Patients Update - Special Access Scheme
August 7, 2023
Australian Patent Granted for RECCE Anti-Infectives
August 3, 2023
Bonus Canadian R&D Rebate Received
July 28, 2023
Scientia Completes Cohort Dosing in Phase I/II UTI Trial
July 28, 2023
Scientia Doses Ahead of Schedule in Phase I/II UTI Trial
July 24, 2023
Clarification - 5x Higher Concentration in Urine & Plasma
July 20, 2023
Phase I Clinical Trial Data Review Complete
July 19, 2023
A$801,604 R&D Rebate Advance Received
July 12, 2023
First Cohort Dosed in Rapid Infusion Phase I/II UTI study
July 10, 2023
Ethics Approval for Phase I/II UTI Trial Expansion
June 29, 2023
Ethics Approval to Start Phase I/II (I.V.) Clinical Trial
April 17, 2023
New Family 4 Patent to be Granted for RECCE Anti-Infectives
April 10, 2023
Recce Receives Further A$973,144 R&D Advance
April 4, 2023
Corporate Presentation - WI Emergence 2023
March 22, 2023
Recce Selects CMAX for Phase I/II UTI Clinical Trial
February 19, 2023
A$6.21m Received from R&D Rebate Payments
January 24, 2023
JP Morgan Healthcare Conference
January 10, 2023
Australian Patent to be Granted for RECCE Anti-Infectives
January 9, 2023
Decks in 2023
- Investor Presentation (September 2023)
Investor deck · 39 slides · September 2023
- World AMR Congress 2023
Conference · 25 slides · September 2023
- Investor Presentation (March 2023)
Investor deck · 25 slides · Mar 23, 2023